MedTrace Logo

Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea

NCT00875875 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2015-06-10

No results posted yet for this study

Summary

The study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either:

1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR
2. a single 600 mg dose of rifaximin daily for 3 days.

Conditions

  • Travelers' Diarrhea

Interventions

DRUG

Rifaximin

Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Charles D Ericsson, MD · University of Texas Medical School at Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00875875 on ClinicalTrials.gov